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Background Medication errors are frequent and
may cause harm to patients and increase
healthcare expenses.
Aim To explore whether a new labelling
influences time and errors when preparing
medications in accordance with medication
charts in an experimental setting.
Method We carried out an uncontrolled before
and after study with 3 months inbetween
experiments. Phase I used original labelling and
phase II used new generic labelling. We set up
an experimental medicine room, simulating a
real-life setting. Twenty-five nurses and ten
pharmacy technicians participated in the study.
We asked them to prepare medications in
accordance with medication charts, place
packages on a desk and document the package
prepared. We timed the operation. Participants
were asked to prepare medications in accordance
with as many charts as possible within 30 min.
Results Nurses prepared significantly more
medication charts with the generic labelling
compared with the original 3.3 versus 2.6
(p=0.009). Mean time per medication chart was
significantly lower with the generic labelling
6.9 min/chart versus 8.5 min/chart (p<0.001).
Pharmacy technicians were significantly faster
than the nurses in both phase I (6.8 min/chart vs
9.5 min/chart; p<0.001) and phase II (6.1 min/
chart vs 7.2 min/chart; p=0.013). The number of
errors was low and not significantly different
between the two labellings, with errors affecting
9.1% of charts in phase I versus 6.5% in phase II
(p=0.5).
Conclusions A new labelling of medication
packages with prominent placement of the
active substance(s) and strength(s) in the front of
the medication package may reduce time for
nurses when preparing medications, without
increasing medication errors.
INTRODUCTION
Medication errors (MEs) include ‘any
preventable event that may cause or lead
to inappropriate medication use or
patient harm while the medication is in
the control of the healthcare professional,
patient or consumer’.1 MEs are consid-
ered one of the most frequent causes of
adverse events in hospitalised patients.2 3
MEs are present throughout the entire
medication administration process, from
prescribing through documenting, tran-
scribing, dispensing, administering and
monitoring.4 European data show that
23% of European Union citizens claim to
have been directly affected by MEs, and
18% claim to have experienced a serious
ME in the hospital.5 Between 50% and
70% of MEs are considered prevent-
able.5 6 Annual costs associated with MEs
are estimated to be £1–2.5 billion in the
UK7 and $2.8–15 million in individual
US medical centres.4
Lookalike/sound-alike (LA/SA) health
products refer to ‘names of health pro-
ducts that have orthographic similarities
and/or similar phonetics (ie, similar when
written or spoken)’.8 These similarities
may cause MEs in relation to prescribing,
dispensing or administration of a
product.8 In USA, confusion between
LA/SA medication names is attributed to
25% of MEs, according to MEs reported
to the US Pharmacopoeia.9 In a study of
400 deaths caused by MEs, the US Food
and Drug Administration (FDA) found
that 5% of deaths were attributed to pro-
prietary name confusion and 4% to
generic name confusion.8
During prescribing and transcribing,
computerised provider order entry
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systems have been promoted as the primary method
to reduce MEs, because misinterpretation of hand-
writing, decimal points or abbreviations can be elimi-
nated.10 After introducing a bar code system in a
medical centre in Virginia, USA, the ME error rate
was reduced by 86% over a 9-year period.10 Despite
the benefits of electronic systems, LA/SA errors may
still be difficult to detect as the prescribed medication
may have been wrongly selected and consequently the
wrong medication dispensed even though presumed
correct by the bar code system.8 Consequently, other
actions may be needed.9 In USA, the FDA has created
a computerised programme that assists in detecting
similar names at the time of market authorisation
application.10 In fact, about one-third of proposed
names for new medications are normally rejected.8
Also, the US Institute for Safe Medication Practices
regularly publishes the ‘List of Confused Drug Names’
to inform healthcare professionals about similar drug
names.11 In addition, error-preventing strategies such
as colour/contrast coded drug administration devices
and ‘Tall-man’ lettering have been suggested.8 9 12 In
Europe, stakeholders in postmarketing monitoring are
urged ‘to identify problems related to poor naming,
labelling, packaging and drug information that occur
with medicines in the day-to-day use’ and ‘to assess
the adequacy of the package design to drug delivery
and administration’.13
The term ‘generic prescribing’ concerns the use of
the international non-proprietary name (INN) of the
active substance(s) when prescribing medications
instead of the brand name marketed by the pharma-
ceutical company. Generic prescribing may reduce
MEs because patients and healthcare personnel can
relate to one name only, the INN, rather than many
different brand names.14 ‘Generic substitution’, is the
term applied to the dispensing of a generic equivalent
medication instead of the prescribed medication.
Generic substitution is possible when the patent life of
the active substance(s) has expired.15 Generic substitu-
tion has been introduced in several countries as a
means to reduce costs of medicines.16 17 In Sweden
and Finland, a 10%–15% reduction in overall medi-
cine costs was observed after implementation of the
mandatory generic substitution policy.16 There is little
evidence that generic substitution interferes with
patient safety.14 15 Still, there are multiple case reports
of patients being admitted to hospital for adverse
drug events resulting from overdoses caused by taking
two or more medications with the same active ingredi-
ent but with different brand names.4 A Norwegian
study showed that 5% of patients on antihypertensive
medications were taking two or more equivalent
generic products simultaneously, mainly because they
believed they were taking different medications.18
To counter the risk of unconsciously taking, admin-
istering or dispensing more than one product with the
same active ingredient, Endestad et al19 recently
explored the effect of a redesigned standardised label-
ling of medication packages. The new design includes
prominent placement of INN(s) and strength(s),
written in black on a white background, and placed in
the upper right corner of the front of the package
(figure 1). In a computer-based experimental study,
the authors investigated the ability of participants to
recognise packages containing the same active ingredi-
ent(s) with original or new labelling. Both younger
and older participants were significantly faster and
more accurate, giving the correct answer with the new
labelling.19
We aimed to explore whether the new labelling sug-
gested by Endestad et al could influence time and
error rates when preparing medications in accordance
with individual medication charts in a hospital setting,
as compared with the original labelling. We also
aimed to study potential differences between nurses
and pharmacy technicians when preparing medica-
tions in order to explore future partnership models to
tackle MEs.
METHODS
The study was performed at the University Hospital
of North Norway (UNN), where medication charts
are handwritten and generic prescribing was intro-
duced in 2012.
We used an uncontrolled before and after design
using the original labelling (phase I) and the new
labelling (phase II) of medication packages. We set up
an experimental medicine room, simulating a real-life
hospital setting. We used medications where the brand
name differed from the generic name and limited the
medications to tablets and capsules. A computer was
available enabling participants to search for active sub-
stances and/or brand names of the different medica-
tions if necessary.
At UNN, the nurses follow a standardised procedure
when preparing medications for patients: (1) read the
handwritten medication chart, (2) select the generic
alternative available, (3) document the selected medica-
tion package in the medication chart with brand name
and signature and (4) administer the medication to the
patient.20 In cases where the brand name equals the
generic name, nurses will also document the manufac-
turer’s name in the chart to exactly identify which
Figure 1 New structured labelling as suggested by Endestad
et al.19
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medication has been prepared and given to the patient.
We included 10 nurses from three hospital depart-
ments (Paediatric, Gastrointestinal Surgery and
Infectious Diseases) in addition to 10 pharmacy techni-
cians from the hospital pharmacy. The same people
participated in both phases of the study.
We prepared 10 different medication charts identi-
cal to the UNN handwritten charts. Each chart
included 10 different medications written with
generic name, strength, dosage interval and dosage
form. We did not validate the charts in terms of
having the same complexity, but the medications were
commonly used in the represented departments. We
asked participants to (1) identify medication packages
in accordance with the medication charts, (2) place
packages on the desk and (3) write brand name (and
manufacturer when appropriate) of medication
packages on the medication chart, following standard
procedure. For every chart prepared, we verified
against the original chart whether the correct medica-
tions had been prepared and the correct names
written. Discrepancies between the medication chart
and the medications prepared were recorded, but not
revealed to participants. We then replaced medications
into shelves and handed out a new medication chart.
Using a stopwatch, we timed the preparing medication
procedure, starting when the chart was handed over
to the participant and stopping when the task had
been completed (figure 2). Participants prepared med-
ications from as many medication charts as possible
within the 30 min allocated time.
In phase I (October 2013), we used original packages
without any additional labelling. In phase II ( January
2014), we labelled the packages with the new standar-
dised generic label as suggested by Endestad et al.19
The label was rectangular and white, covering about
25% of the package, and placed in the upper right
corner. INN(s) and strength(s) were written in Arial
point 24 bold and in Arial point 18, respectively
(figure 1). Drug formulation was not included. We
used label sizes in accordance with package sizes, some-
times descaling the size of the letters in order to make
the label cover only 25% of the package front.
Statistics
We used Microsoft Office Excel V.15.27 and SPSS
24.0 for Windows for data management and analysis.
Continuous variables were expressed with means and
SD, medians and minimum and maximum values.
Data were not normally distributed, and we applied
non-parametric statistical tests. We used the Wilcoxon
signed-rank (WSR) test to compare time per medica-
tion chart in between the two phases, only including
medication charts completed by the same participant
in both phases. The Mann-Whitney U (M-W) test was
applied to compare mean time and mean number of
medication charts prepared between groups, including
all medication charts from both phases. We applied
Fischer0s exact (FE) test to explore differences in error
rates per medication chart between the two phases,
including all medication charts from both phases. A
value of p<0.05 was considered significant.
Sample size
We calculated sample size based on parametric data
and estimated average speed of 0.5 min to prepare a
single medication from a medication chart. We aimed
to show a 20% reduction in speed (from 0.5 to
0.4 min). Comparing differences between means using
SDs from 0.2 to 0.5, we estimated a sample size of 34
to 199, respectively. As SD was unknown, and we
only had 30 min allocated per participant, we decided
to prepare 100 medications: 10 medication charts
with 10 medication in each, then also taking into con-
sideration that some participants would be faster than
average.
Ethics
The project was presented to the Regional
Committees for Medical and Health Research Ethics,
who concluded that no ethical approval was necessary.
Participants accepted participation on request from
their leaders (oral consent only), briefly presented
with the aim of the study and what they were
expected to do. No direct personal identifiable data
were collected, but participants were given consecu-
tive study numbers to allow for comparison between
the two phases.
Figure 2 Experimental procedure in a simulated medicine
room. *n represent the number of medication charts the
participant was able to prepare during the allocated time.
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RESULTS
A total of 40 participants arrived for phase I, but only
35 for phase II––25 nurses and 10 pharmacy techni-
cians. Only one participant (from department III) was
male. The reason for non-participation is unknown.
See table 1 for demographic variables.
In total, participants prepared medications from 99
medication charts in phase I (range 1–5), and from
124 in phase II (range 2–7). In phase II (generic label-
ling), participants prepared medications from signifi-
cantly more medication charts compared with phase I
[mean 3.5 charts (SD 1.4), median 3.0 vs mean 2.9
charts (SD 1.0), median 3.0; p=0.024 (M-W)].
Among nurses, the number of medication charts pre-
pared increased significantly from phase I to phase II
[mean 2.6 charts (SD 0.8), median 2.0 vs mean 3.3
charts (SD 1.1), median 3.0; p=0.009 (M-W)], which
was not the case among pharmacy technicians (mean
3.6 charts (SD 1.2), median 3.5 vs mean 4.1 charts
(SD 1.8), median 4.0; p=0.67 (M-W)]. While phar-
macy technicians prepared medications from signifi-
cantly more medication charts compared with nurses
in both phases, the difference between the two profes-
sions was significant only in phase I [p=0.011
(M-W)], and not in phase II [p=0.255(M-W)].
Time spent preparing medication charts was signifi-
cantly reduced in phase II (generic labelling) compared
with phase I (original labelling); mean 6.9 min/chart
(SD 2.7), median 6.5 vs mean 8.5 min/chart (SD 3.5),
median 8.4; p<0.001 (WSR). Time reduction from
phase I to phase II was significant among nurses from
all departments, but not among pharmacy technicians
(figure 3). The nurses spent significantly more time
than the pharmacy techicians in phase I [mean
9.5 min/chart (SD 3.7), median 9.3 vs mean 6.8 min/
chart (SD 2.5), median 6.3; p<0.001 (M-W)]. This dif-
ference was smaller in phase II, but still significant
[mean 7.2 min/chart (SD 2.6), median 6.9 vs mean
6.1 min/chart (SD 2.6), median 5.2; p=0.013 (M-W)].
We identified errors in 6.5% of the charts (n=8) in
phase II vs 9.1% of the charts (n=9) in phase I
[p=0.462 (FE)]. We never identified more than one
error in each chart, but two participants made two
errors in phase I. In phase I, we identified errors in
11.1% (n=7) of the charts prepared by nurses and
5.6% (n=2) of the charts prepared by pharmacy tech-
nicians. This was the opposite in phase II, where we
identified errors in 9.8% (n=4) of the charts prepared
by pharmacy technicians and 4.8% (n=4) of the
charts prepared by nurses. The difference between
nurses and pharmacy technicians was not statistically
significant in either parts [p=0.357 and 0.294,
respectively (FE)]. Two types of errors changed
slightly from phase I to II. Errors involving medica-
tions as fixed dose combinations were reduced from
eight in phase I to two in phase II. Errors involving
medications with a different active substance were
absent in phase I, but occured three times in phase II.
For an overview of errors, see table 2.
DISCUSSION
The present study shows that a new standardised
generic labelling of medication packages as suggested
by Endestad et al19 may reduce time for nurses when
preparing medications in accordance with medication
charts, without increasing MEs.19 To our knowledge,












Female 7 9 8 10 34 (97.1)
Age
20–29 7 (20.0) 1 (2.9) 7 (20.0) 1 (2.9) 16 (45.7)
30–39 – 3 (8.6) 1 (2.9) – 4 (11.4)
40–49 – 1 (2.9) 1 (2.9) 1 (2.9) 3 (8.6)
50–59 – 3 (8.6) – 6 (17.1) 9 (25.7)
60+ – 1 (2.9) – 2 (5.7) 3 (8.6)
Education
High school /college* – – – 10 (28.6) 10 (28.6)
University <4 years 6 (17.1) 1 (2.9) 8 (22.9) – 15 (42.9)
University >4 years 1 (2.9) 8 (22.9) 1 (2.9) – 10 (28.6)
Experience with handling medications (years)
<1 5 (14.3) – 5 (14.3) – 10 (28.6)
1–5 2 (5.7) 1 (2.9) 2 (5.7) – 5 (14.3)
6–10 – – 1 (2.9) 1 (2.9) 2 (5.7)
>10 – 8 (22.9) 1 (2.9) 9 (25.7) 18 (51.4)
*Pharmacy technician education is a 1–2 year college education.
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no study has previously explored the consequences of
a new standardised labelling on time and MEs when
nurses prepare medications in a simulated setting. Nor
do we know of any study comparing nurses and phar-
macy technicians performing this task.
MEs such as missed dose, wrong dosage, wrong
medication, wrong time and wrong route frequently
happen during hospitalisation and may lead to patient
harm and additional healthcare costs.4 A stressful
work environment for nurses may predispose for MEs
when preparing medications.17 Our study indicates
that medication workload time for nurses may be
reduced if generic labelling is used.
Another way to reduce nurses’ medication workload
time and MEs could be to use pharmacy technicians
in medication management tasks. A UK pilot study
described positive results from a model where nurses
and pharmacy technicians formed a partnership in
preparing and double-checking medications for intra-
venous administration.21 The collaboration increased
the understanding of medication safety and confi-
dence in their delivering of care, and also reduced
medication safety incidents.21 A US study showed that
engaging pharmacy technicians with patients and
nursing staff in a paediatric unit could reduce the time
nurses spent ‘hunting for medications’.22 In our study,
pharmacy technicians were significantly faster than
nurses, independent of labelling. As a means to tackle
MEs, we should rethink the role of the pharmacy
technicians also in Norway and other countries.
In our study, error rates were low and not signifi-
cantly different between the two labelling periods.
However, results may be limited by the low error
rates, and a larger study may be necessary to verify
our findings. The most frequent errors in our study
involved preparing single-substance medications
Figure 3 Mean time (minutes) per medication chart when preparing medications in accordance with medication charts in phase I
(original labelling) and phase II (generic labelling).
Table 2 Errors made when preparing medications in accordance with medication charts in phase I (original labelling) and phase II
(generic labelling)
N Medicine package erroneously prepared Medication package that should have been prepared
Errors phase I 7 Norvasc (amlodipine), tablet, 5 mg Exforge (amlodipine/valsartan), tablet, 5 mg/160 mg
1 Pentasa (mesalazine), slow release tablet, 500 mg Mezavant (mesalazine), tablet, 1200 mg
1 Atacand (candesartan), tablet, 8 mg Atacand Plus (candesartan/hydrochlorothiazide), tablet, 8 mg/12.5 mg
Summary phase I: 9 errors in 99 medication charts (9.1%) 7 made by nurses (11.1%
of charts) 2 made by pharmacy technicians (5.6% of charts)
Errors phase II 3 Pentasa (mesalazine), slow release tablet, 500 mg Mezavant (mesalazine), tablet, 1200 mg
1 Norvasc (amlodipine), tablet, 5 mg Exforge (amlodipine/valsartan), tablet, 5 mg/80 mg
1 Valcyte (valganciclovir), tablet, 450 mg Valtrex (valaciclovir), tablet, 500 mg
1 Atacand (candesartan), tablet, 8 mg Atacand Plus (candesartan/hydrochlorothiazide), tablet, 8 mg/12.5 mg
1 Atarax (hydroxyzine), tablet, 25 mg Atacand (candesartan), tablet, 8 mg
1 Atarax (hydroxyzine), tablet, 25 mg Arava (leflunomide), tablet, 20 mg
Summary phase II: 8 errors in 124 medication charts (6.5%) 4 made by nurses (4.8%
of charts) 4 made by pharmacy technicians (9.8% of charts)
Original research
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instead of the correct fixed-dose combination (LA/
SA), followed by wrong formulation and strength.
Except from the single-substance versus fixed-dose
combination errors made in the generic labelling
phase, three other LA/SA errors were made. The
mix-up was comprehensible in the case where both
brand names and generic names were similar, but
harder to comprehend in the two cases where the
generic names were totally different. Even if the
brand names were similar, participants were supposed
to use the generic names to locate the medication
packages and not the brand names. One plausible
explanation for this mix-up is that participants trans-
lated the generic names into brand names even if the
packages were labeled with generic names, and subse-
quently prepared the wrong medication due to LA/SA
brand names. This type of error has also been
reported by Anto et al,12 although not being very
frequent.
We found no significant difference in error rates
between nurses and pharmacy technicians; however,
this may also be limited by the low error rates.
Compared with nurses who are personally responsible
for giving correct medications to patients, pharmacy
technicians normally operate further away from the
patient and always under control by a pharmacist.
Consequently, we believe that pharmacy technicians
involved in clinically related tasks should be offered
training which also focuses on direct patient responsi-
bility. This was also the case in the UK study where a
training programme was initiated.21
A slow release tablet with the wrong strength was
four times erroneously prepared instead of an imme-
diate release tablet, suggesting that the drug formula-
tion should be included in the new labelling in
addition to the INN(s) and strength(s), as originally
suggested by Endestad et al.19 Information about drug
formulation is important both due to effect and safety.
Strengths and limitations
The main strength of this study is the standardised
experimental design. In both phases, we used the
same medicine room, the same medication packages,
the same medication charts, the same procedure, the
same instructions and instructors, and the same
amount of time available for each participant. The
main limitation of this study is the uncontrolled
before and after design. Even if quasiexperimental
studies are considered superior to observational
studies, they are limited by the difficulty in attributing
the observed change to the intervention (in this case
the new labelling).23 In this study, we tried to minim-
ise recall bias from phase I by waiting 3 months to
perform phase II, but results should be interpreted
with care as we cannot rule out the possibilities of a
learning effect. However, none of the participants had
any information about the new labelling design before
phase II. Hawthorn effects could also have introduced
biases.23 Some participants may have worked faster
than normal due to stress and a desire to perform,
resulting in more mistakes. Others may have worked
slower than normal in order to make as few errors as
possible. Whether this influenced the difference
between the two phases or between nurses and phar-
macy technicians is unknown. However, the number
of errors observed in phase I is in line with the
number of errors seen when nurses documented
errors during double-checking (unpublished data for
UNN showing errors in 12.1% of medication charts),
indicating that the experimental setting resembled
reality. Finally, our study lacks power to identify a stat-
istical significant difference in error rates between the
two phases. A follow-up study should take these issues
into consideration and perhaps use a cross-over
design. Sample size should be increased by including
more medication charts, and the study should be per-
formed in a real-life situation.
CONCLUSION
A new labelling of medication packages with prominent
placement of the active substance(s) and strength(s) may
reduce time for nurses when preparing medications
without increasing MEs. We do however suggest adding
information about drug formulation to the label to
further minimise risk of confusion. Due to pharmacy
technicians’ efficiency and knowledge about medica-
tions, innovative collaboration structures between phar-
macy technicians and nurses should be investigated.
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